Literature DB >> 32968239

Biomarkers 101 - personalizing therapy for RCC.

David Killock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32968239     DOI： 10.1038/s41585-020-00380-x

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

Authors:  Robert J Motzer; Paul B Robbins; Thomas Powles; Laurence Albiges; John B Haanen; James Larkin; Xinmeng Jasmine Mu; Keith A Ching; Motohide Uemura; Sumanta K Pal; Boris Alekseev; Gwenaelle Gravis; Matthew T Campbell; Konstantin Penkov; Jae Lyun Lee; Subramanian Hariharan; Xiao Wang; Weidong Zhang; Jing Wang; Aleksander Chudnovsky; Alessandra di Pietro; Amber C Donahue; Toni K Choueiri
Journal:  Nat Med       Date:  2020-09-07       Impact factor: 53.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.